Professor John Brazier and Professor Ben van Hout will be attending the 21st Annual Meeting of ISPOR in Washington next week. John is running a short course on Utility Measures with Breandan Mulhern. Ben is presenting a paper on the Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States.
Professor van Hout will also be promoting our MSc International Health Technology Assessment as part of his role as the course’s Stategic Lead for Academic Studies. Ben is also Scientific Director at Pharmerit International, so if you want to talk about our MSc, you will be able to find him, and more information, at Booth 84/85.